Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

0.5629 +0.0629 (+12.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,171,533
Open 0.5200
Bid (Size) 0.5400 (10)
Ask (Size) 0.5500 (48)
Prev. Close 0.5000
Today's Range 0.5000 - 0.5700
52wk Range 0.4401 - 9.860
Shares Outstanding 164,874,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Epizyme To Participate in H.C. Wainwright Global Investment Conference
From Epizyme, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million. 
Via Benzinga

Performance

YTD
-79.00%
-79.00%
1 Month
-21.61%
-21.61%
3 Month
-62.72%
-62.72%
6 Month
-87.00%
-87.00%
1 Year
-93.75%
-93.75%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
30 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Epizyme: Q1 Earnings Insights
Via Benzinga
99 Biggest Movers From Yesterday
Via Benzinga
Recap: Epizyme Q4 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Epizyme Earnings Preview
Via Benzinga
Epizyme Announces Date of First Quarter 2022 Financial Results
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
From Epizyme, Inc.
Via Business Wire
Epizyme's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Insiders Buying Pixelworks And 4 Other Penny Stocks
Via Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.